The National Medical Products Administration approved the listing of Renigiaolun Injection.

Recently, the National Medical Products Administration approved the application of Shanghai Hengrunda Life Sciences Co., Ltd. for the market authorization of Lenigeorgiolonsei injection, used for the treatment of relapsed or refractory diffuse large B-cell lymphoma in adults after second-line or higher systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, follicular lymphoma transformed into diffuse large B-cell lymphoma, high-grade B-cell lymphoma with MYC and BCL2 rearrangements, and high-grade B-cell lymphoma not otherwise specified.